Testosterone Therapy Changes
US Health Agency Requests Major Label Revisions for Men's Testosterone Therapy
The US Department of Health and Human Services is asking drugmakers to update the labels on testosterone replacement therapies, a move that could make it easier for millions of American men to get the treatment HHS Press Office. On June 18, 2026, HHS Secretary Robert F. Kennedy Jr. formally requested the changes, saying the goal is "putting science back at the center of men's healthcare."
The most significant change: removing a decade-old statement that said testosterone therapy's safety and effectiveness had not been established for men with age-related low testosterone WLWT. Experts say the shift could affect millions of men aged 45 to 80 who struggle with fatigue, low sex drive, and mood changes.
A 2023 Trial Rewrote What We Know About TRT
The label changes are largely driven by the TRAVERSE trial, published in the New England Journal of Medicine in June 2023 NEJM. The study followed 5,246 men and found no significant increase in major heart events or prostate cancer among men using testosterone therapy compared to those taking a placebo.
The FDA had actually required that trial back in 2015 to settle a safety debate. Once the results came in, the agency moved quickly. By February 2025, the FDA removed a cardiovascular warning from testosterone drug labels based on the TRAVERSE data FDA Press Office. The new HHS request builds on that shift.
What the Label Changes Actually Say
HHS is asking for three main updates. First, remove the line saying the therapy's safety is unproven for age-related low testosterone. Second, revise warnings about enlarged prostate. Third, update information about prostate cancer risk KETV. Current labels warn against using testosterone therapy in men with known or suspected prostate cancer.
The FDA is also encouraging drug companies to seek approval for a new use: treating low libido in men with idiopathic hypogonadism — that is, low testosterone with no known cause FDA.gov. That announcement came on April 16, 2026, and signals how far the agency's position has shifted since 2015.
Doctors Applaud but Urge Caution Before Starting Therapy
Many doctors welcomed the news. Dr. Jamin Brahmbhatt of Orlando Health called it "science finally catching up to reality" CNN. Dr. Eddie Hackler III added that removing the old warning "removes the fear" for clinicians who had long been wary of prescribing the therapy. Still, both doctors stressed that a proper diagnosis must come first.
Dr. Brahmbhatt put it plainly: "Taking a warning off a label isn't the same as saying every man should be on it" CNN. Experts across the board agree that men should have a full conversation with their doctor before starting testosterone therapy — including blood tests to confirm low levels.
Critics Warn of Pharmaceutical Influence, Insurance Windfall
Not everyone is on board. The consumer advocacy group Public Citizen filed formal objections to the review process, arguing that several panelists had "direct ties to pharmaceutical companies" Public Citizen. Critics say the FDA is relying too heavily on a single industry-linked trial to make sweeping regulatory changes.
The financial stakes are enormous. The US testosterone therapy market was worth $2.1 billion in 2025 and is projected to top $2.5 billion by 2030 IMARC Group. Insurers often used the old "safety not established" label language to deny coverage for age-related low testosterone. Removing that language could open the door to far wider insurance coverage — and far higher costs.
Sentiment
NeutralPublishers
7
Articles
7
Reach
7
